Endogenous insulin production is preserved in Type 1 diabetes with anti-TNF drug

June 16, 2020

BUFFALO, N.Y. - In research led by a University at Buffalo pediatric endocrinologist, a drug called golimumab showed that it preserved beta-cell function in children and young adults with newly diagnosed Type 1 diabetes, according to findings from a Phase 2 study.

The study also demonstrated that golimumab, an anti-tumor-necrosis-factor (TNF) therapy, reduced the amount of injected insulin required by children and young adults with newly diagnosed Type 1 diabetes by preserving their ability to produce insulin on their own, called endogenous insulin. The World Without Disease Accelerator, through Janssen Research & Development, LLC, funded the study.

Golimumab, marketed as Simponi®, is currently used in the treatment of rheumatoid arthritis, ulcerative colitis and other autoimmune conditions, however it is not approved by the U.S. Food and Drug Administration for the treatment of Type 1 diabetes.

The findings were presented on June 13 at the annual meeting of the American Diabetes Association by the lead investigator, Teresa Quattrin, MD, UB Distinguished Professor in the Department of Pediatrics, senior associate dean for research integration in the Jacobs School of Medicine and Biomedical Sciences at UB and attending pediatric endocrinologist at the Diabetes Center at UBMD Pediatrics and John R. Oishei Children's Hospital.

"This study shows that golimumab is a potential disease-modifying agent for newly diagnosed patients with Type 1 diabetes," said Quattrin. "The main goal of the study was to see if golimumab could preserve beta-cell function in these newly diagnosed patients."

Measuring how well the pancreas is working

This was assessed by measuring the amount of C-peptide in patients' blood during a four-hour mixed meal tolerance test. Because C-peptide reflects only insulin made by the body and not injected insulin, C-peptide levels reveal how well the pancreas is producing insulin.

Patients treated with golimumab had a higher C-peptide level at week 52 compared to placebo. "This was statistically significant, thus the study met its primary goal," Quattrin said, "in fact, 41.1% of participants receiving golimubab had an increase or less than 5% decrease in C-peptide compared to only 10.7% in the placebo group."

Good control with less insulin

Nearly 43% of those who received golimumab were in partial diabetes remission (also known as the honeymoon phase) versus 7.1% of those receiving placebo. The definition of partial remission was based on insulin dose and blood sugar control levels as indicated by hemoglobin A1C, a measurement of average blood sugar levels over three months.

Quattrin explained that a child with Type 1 diabetes requires about 1 unit of insulin per kilogram of body weight per day. That means that a child weighing about 65 pounds typically requires about 30 units of injected insulin per day once they are out of the partial remission period, about 3-6 months after diagnosis.

"In this study, both golimumab and placebo groups achieved good blood sugar control, but patients treated with golimumab achieved it with less insulin," said Quattrin. "During the 52 weeks, insulin dose increased only slightly for those on golimumab, 0.07 units per kilogram per day, versus 0.24 units per kilogram per day for those on placebo study. Moreover, in a post-hoc analysis, an analysis conducted after the conclusion of the clinical trial, those who were younger than 18 years had 36% fewer episodes where blood sugar was less than 54 mg per deciliter, designated by the American Diabetes Association as level 2 hypoglycemia," Quattrin said.

This is important clinically because low blood sugar reactions are dangerous and can even be fatal if untreated. Low blood sugars require immediate attention, often causing the child to be removed from class or recreation activities compromising quality of life.

The drug is self-administered as a subcutaneous injection every 2 weeks. No serious side effects related to the study drug, such as serious infections, were reported.

The randomized, controlled clinical trial was conducted at 27 centers throughout the U.S., including at the Diabetes Center at UBMD Pediatrics and Oishei Children's Hospital in Buffalo. It involved 84 patients, aged 6 to 21 years, with two-thirds receiving golimumab and one-third receiving placebo starting within 100 days from diagnosis.

Throughout three decades as a leading researcher in pediatric endocrinology, Quattrin has been interested in finding ways to preserve beta-cell function in newly diagnosed patients with Type 1 diabetes.

The current study took place on the basis of positive findings in animal models, as well as Quattrin's work with patients treated at the Diabetes Center at UBMD Pediatrics and Oishei Children's Hospital. It confirms results published by her team in 2009 where in a randomized pilot study 10 patients received another TNF inhibitor and 8 received placebo starting within 28 days from diagnosis. The results of this small proof of concept study strongly suggested that this class of drugs might be able to preserve beta-cell function in newly diagnosed patients with Type 1 diabetes.
UB co-investigators in the clinical trial presented at the ADA are Lucy Mastrandrea, MD, PhD, Kathy Bethin, MD, PhD, Indrajit Majumdar, MD, John Buchlis, MD and Christine Albini, MD PhD. Quattrin noted that they were supported by an outstanding pediatric diabetes-endocrinology research team led by Amanda House.

Co-authors from other institutions include Michael J. Haller of the University of Florida; Andrea K. Steck of the University of Colorado ; Eric I. Felner of Emory University; and Yinglei Li, Yichuan Xia, Jocelyn H. Leu, Ramineh Zoka, Joseph A. Hedrick, Mark R. Rigby and Frank Vercruysse, all of Janssen Research & Development, LLC.

University at Buffalo

Related Diabetes Articles from Brightsurf:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.